Calls for papers
-
Phillips Medisize announced that its parent company Molex has completed its acquisition of inhalation CDMO Vectura, which was initially announced in September 2024. According to the announcement, the acquisition covers all of Vectura’s assets in… Read more . . .
-
Arcturus Therapeutics announced that it initiated 2 studies in December 2024, one of which is a Phase 2 MAD trial of ARCT-032 inhaled mRNA therapy in cystic fibrosis patients. The company announced in September 2024 that… Read more . . .
-
ARS Pharmaceuticals announced that it has submitted marketing applications for neffy epinephrine (adrenalin) nasal spray in Canada and in the UK. The nasal spray has been approved in the US and in Europe (as EURneffy) for the… Read more . . .
-
Endo USA has recalled all unexpired lots of Adrenalin Chloride Solution epinephrine nasal solution, which is meant for topical application, due to FDA concerns about the potential for confusion of the product with the company’s… Read more . . .
-
Aridis Pharmaceuticals said that “an undisclosed pharmaceutical company” has agreed to pay $6.5 million plus annual royalty payments for Aridis’ AR-501 nebulized gallium for the treatment of chronic lung infections in patients with cystic fibrosis.… Read more . . .
-
The US Court of Appeals for the Federal Circuit has upheld a ruling from district court that requires Teva to remove patents covering inhaler device and dose counter IP from the FDA’s Orange Book. In… Read more . . .
-
DDL 2024 drew the largest crowd ever in the 35-year history of the Drug Delivery to the Lung (DDL), with more than 100 OINDP experts attending online and approximately 1,000 attending in person at the… Read more . . .
-
Savara announced that it has initiated a rolling biologics license application submission for its Molbreevi molgramostim inhalation solution for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). The company said that it will request priority review… Read more . . .
-
According to PureIMS, both the EMA and FDA have recently granted orphan drug designation to the company’s Colistin Cyclops dry powder inhaler for the treatment of P. aeruginosa infections in cystic fibrosis patients. Colistin Cyclops is… Read more . . .
-
Intranasal drug developer Orexo and Swedish vaccine developer Abera Bioscience have announced that they will collaborate on development of intranasal dry powder vaccines based on Orexo’s AmorphOX powder engineering technology and Abera’s vaccine platform, starting… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan